Spike Loy Acquires Shares of MoonLake Immunotherapeutics

Spike Loy made a notable move by purchasing 22,195 shares of MoonLake Immunotherapeutics, trading under the ticker MLTX on the NasdaqCM, on June 17, 2026. This transaction did not specify a value or price per share, but it reflects Loy's interest in the biotechnology company.

MoonLake Immunotherapeutics Stock Snapshot

Shares of NasdaqCM:MLTX were trading at $19.19. MoonLake Immunotherapeutics has a market capitalization of about $1.41 billion. The company's forward P/E ratio is not meaningful as it isn't profitable, and its beta is 1.036, indicating moderate volatility. The stock's 52-week range has been between $5.95 and $62.75, with a 50-day moving average of $17.88 and a 200-day moving average of $19.01. MoonLake maintains a strong current ratio of 8.601 and a quick ratio of 7.887, with a debt-to-equity ratio of 39.682.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company based in Zug, Switzerland. It focuses on developing innovative therapies for inflammatory skin and joint diseases. The company is advancing Sonelokimab, a novel treatment targeting IL-17A and IL-17F for conditions such as hidradenitis suppurativa, psoriatic arthritis, and psoriasis. Founded in 2021, MoonLake is led by CEO Dr. Jorge Santos da Silva and employs around 130 people.

Bottom Line

Spike Loy's acquisition of shares in MoonLake Immunotherapeutics signals a continued interest in this innovative biotech firm. Investors closely track insider transactions like these for potential insights into company prospects. As a reminder, this information reflects Loy's position as of the transaction date and may not represent current holdings.